← boardnext 2026-09-28
MLTX
MoonLake Immunotherapeutics AGdistress 4/10 · elevated risk$18.62-2%today-70% from 52w high
Immunology / Inflammation 2
Lead: Hidradenitis Suppurativa · target IL-17
Revenue
pre-revenue
Liquidity
$298M
Runway
1.3 yrs
Shares 1y
—
Price & events
+19.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.7%
1D
-2.1%
1W
-12.3%
1M
+10.0%
3M
+17.4%
6M
-66.6%
1Y
-59.3%
2Y
+86.2%
5Y
+71.8%
All
Overview
- Market Cap
- $1.37B
- Enterprise Value
- $1.17B
- Volume
- 59.44K
- 52 Week Range
- $6.25 – $61.99
- Total Shares
- 73.62M
- Float Shares
- 43.69M
- Short %
- 10.89%
- % Held by Insiders
- 8.58%
- % Held by Institutions
- 79.71%
- RVOL
- 0.04x
- Beta
- 1.04
Pipeline stages · 1 programs
Sonelokimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 8 trials · 5 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09-28 Estimated 50% readout ~2026-12-12 | Phase 3 | Sonelokimab | Hidradenitis Suppurativa | — | active not recruiting |
| 2027-01-15 Estimated 50% readout ~2027-03-31 | Phase 3 | Sonelokimab, Risankizumab | Arthritis, Psoriatic | — | recruiting |
| 2027-02-04 Estimated 50% readout ~2027-04-20 | Phase 3 | Sonelokimab | Arthritis, Psoriatic | — | active not recruiting |
| 2028-02-04 Estimated 50% readout ~2028-04-19 | Phase 3 | Sonelokimab | Arthritis, Psoriatic | — | enrolling by invitation |
| 2028-06-13 Estimated 50% readout ~2028-08-27 | Phase 3 | Sonelokimab | Hidradenitis Suppurativa | — | enrolling by invitation |
Show all 8 trials · 3 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-11-01 | Phase 1 | Sonelokimab | Relative Bioequivalence | 120 | completed |
| 2025-09-02 | Phase 3 | Sonelokimab | Hidradenitis Suppurativa | 422 | completed |
| 2025-08-14 | Phase 3 | Sonelokimab | Hidradenitis Suppurativa | 418 | completed |
Catalyst news & presentations · 10
- H2 2026Guided 55%readoutPhase 3sonelokimab · Primary endpoint readout of Phase 3 IZAR-2 trial.SEC 8-K
- H2 2026Guided 55%regulatory submissionFiled (NDA/BLA)sonelokimab · BLA submission for sonelokimab in HS.SEC 8-K
- end of September 2026Estimated 45%regulatory submissionFiled (NDA/BLA)sonelokimab · BLA submission for SLK in HSSEC 8-K
- 2026-08-04Estimated 45%earningsEarningsEarnings releaseyahoo
- Mid 2026readoutPhase 3sonelokimab · Primary endpoint readout of Phase 3 IZAR-1 trial.SEC 8-K
- 2026-05-10fda agreementsonelokimab · Final pre-BLA meeting with FDA, alignment on submission plans and label strategy for sonelokimab in hidradenitis suppurativa.SEC 8-K
- Q1 2026readoutPhase 2sonelokimab · Primary endpoint readout of Phase 2 S-OLARIS trial.SEC 8-K
- 2026-01-08fda agreementsonelokimab · FDA agreed that substantial evidence of effectiveness can be established with existing VELA-1, VELA-2, and MIRA trials; no additional trials needed for HS BLA.SEC 8-K
- summer 2025readoutPhase 3sonelokimab · Expected primary endpoint readout for VELA-1 and VELA-2 Phase 3 studies.SEC 8-K
- April 29, 2025conferencedata presentationsecondaryCapital Markets Update in New York to discuss Hercules partnership and provide clinical updates, including VELA readout date and LEDA interim data.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $28 (+50% upside) · 13 analysts
- 2026-07-20HC Wainwright & Co.Buy
- 2026-07-01Leerink PartnersOutperform
- 2026-06-09BTIGBuy
- 2026-06-08HC Wainwright & Co.Buy
- 2026-05-12NeedhamBuy
- 2026-05-11HC Wainwright & Co.Buy
Competitors — IL-17
- none identified
Recent news
- 2026-07-22Form 4 MoonLake Immunotherapeutics For: 21 July By Investing.com - Investing.com Nigeria
- 2026-07-21MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data - Stocktwits
- 2026-07-20MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event - Stocktwits
- 2026-07-20H.C. Wainwright reiterates Moonlake stock buy rating on funding - Investing.com
- 2026-07-20H.C. Wainwright reiterates Moonlake stock buy rating on funding - Investing.com
- 2026-07-20MoonLake Immunotherapeutics (NASDAQ: MLTX) CSO entity sells 16,105 shares - Stock Titan
- 2026-07-20MoonLake Immunotherapeutics CSO Kristian Reich sells 16,105 shares for $322,261.05 - Bitget
- 2026-07-20Behavioral Patterns of MLTX and Institutional Flows - Stock Traders Daily
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.